Sanchitongshu
PreclinicalSmall molecule
Sanchitongshu is one of 38 small molecule programs targeting Transient Ischemic Attack. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
116 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Atorvastatin Calcium
Merck & Co.Phase 3
Aggrastat
MMedicure
Phase 3
SGLT-2 Inhibitors
Novo NordiskPhase 3
PPA Intervention
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Tenecteplase or Alteplase
IInsel Gruppe AG, University Hospital Bern
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Transient Ischemic Attack1 trial
Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT02975076·120 enrolled
Ischemic stroke1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sanchitongshu. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details